Antikor to present at the European Partnering and Investment Conference, London, UK.

Dr Deonarain will introduce the newly formed company to potential investors and partners, and talk about the use of Antikor’s OptiLinkTM platform in the field of Fragment-based Antibody-Drug Conjugates. Alone, and in collaboration with partner organisations, Antikor is developing a new therapeutic platform combining the advantageous properties of antibody fragments with a proprietary technology to increase dramatically the number of warhead molecules loaded onto these fragments. This will significantly improve the therapeutic window of ADCs by simultaneously increasing potency through increased cell killing and tumour penetration, and decreasing off-target effects as a result of the absence of an Fc domain and the ability to tailor the drug’s pharmacodynamics properties. In time, it is anticipated that this will result in marketed drugs exhibiting a far better treatment outcome for patients, as well as a reduction in the debilitating side-effects often experienced during the treatment regime. 


Events / Conferences

Notes to Editors

  1. www.epicbiotech.com
  2. For more information on Antikor’s technology, please contact: Dr Mahendra Deonarain, Antikor Biopharma Ltd, Stevenage Bioscience Catalyst, Gunnels Wood Rd, Stevenage, Hertfordshire SG1 2FX, UK. Email: m.deonarain@antikor.co.uk.

About Antikor

Antikor Biopharma Ltd is a private multidisciplinary biopharmaceutical company spun out from Imperial College London. The company is located at the Stevenage Bioscience Catalyst on the GSK site close to the life science clusters of Cambridge and London. The company is leveraging technologies acquired from Photobiotics (now a subsidiary company) in the development of more effective Antibody-Drug Conjugates in the treatment of numerous cancers and in other therapeutic areas.

About Antibody-Drug Conjugates

Antibody Drug Conjugates (ADCs) are a relatively new type of therapeutic comprising a targeting molecule (an antibody) linked to a cytotoxic drug. When a patient is treated with an ADC, the antibody specifically directs the drug to the tumour cell and kills it. Traditional chemotherapeutic agents cannot be specifically targeted in this way. ADC targeted therapy is one of the most rapidly expanding areas in the biotech sector, with numerous significant partnership deals in place. Two current next generation ADCs, Kadcyla and Adcetris, have been approved recently in breast cancer and lymphoma, respectively, and other drug candidates are in the development pipeline. Major pharmaceutical companies are taking a real interest in this field, leading to licensing opportunities for biotechnology companies specialising in antibody-drug conjugation technologies.